Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aldesleukin - Assistance Publique Hopitaux de Paris/ILTOO Pharma

Next Previous
Drug Profile

Aldesleukin - Assistance Publique Hopitaux de Paris/ILTOO Pharma

Alternative Names: ILT-101; Interleukin-2 - Assistance Publique Hopitaux de Paris/ILTOO Pharma; ld-IL2; Low dose il2 - Assistance Publique Hopitaux de Paris/ILTOO Pharma; Low dose rhIL2 - Assistance Publique Hopitaux de Paris/ILTOO Pharma; Low-dose interleukin-2 - Assistance Publique Hopitaux de Paris/ILTOO Pharma

Latest Information Update: 07 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
  • Developer Assistance Publique Hopitaux de Paris; ILTOO Pharma
  • Class Antiallergics; Antihyperglycaemics; Antineoplastics; Antipsychotics; Immunotherapies; Interleukins; Mood stabilisers; Recombinant proteins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinoconjunctivitis; Amyotrophic lateral sclerosis; Autoimmune disorders; Bipolar disorders; Hypersensitivity; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Phase I/II Spontaneous abortion

Most Recent Events

  • 03 Jun 2026 Efficacy and adverse events data from a phase I/II FACL-2 trial in Spontaneous abortion presented at the 27th Annual Congress of the European League Against Rheumatism (EULAR-2026)
  • 01 May 2026 Assistance Publique Hopitaux de Paris plans a phase I/II THERIPEX trial for Immunological-disorders (In neonates, In children, In infants, In adults, In adolescents) in France (IV, infusion) in May 2026 (CTIS2025-523305-15-00)
  • 01 Oct 2025 Assistance Publique Hopitaux de Paris plans a phase II ALaDIN trial for Autism spectrum disorder (In children) in France (SC), in October 2025 (CTIS2025-522841-23-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top